CD22 and congenital rubella syndrome: More importantly, the dose of CD22 CAR-T cells infused in the humanized group with higher efficiency was significantly lower than that in the murinized group, as the first few patients who received the lowest dose of humanized CAR T-cell cocktail therapy achieved satisfactory efficacy, and one case of grade 3 CRS.